Adu-CAN-umab? Reading The Tea Leaves For Biogen’s US Filing For Alzheimer’s Drug

 
• By Michael McCaughan

The US Food and Drug Administration is expediting the review for Biogen’s Alzheimer’s therapy aducanumab, setting up a likely November/December advisory committee consideration that in normal times would be the dominant topic for those who care about the agency.

Priority Stamp
The US FDA has made clear the review of Biogen's aducanumab application is a priority, but is it approvable? • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers